What is Rapalogix Health?
Based in California, Rapalogix Health operates at the intersection of biotechnology and advanced skincare. The company is dedicated to translating foundational longevity science into clinical-grade dermatological solutions. By leveraging its proprietary pro-longevity molecule, RLX-201, Rapalogix aims to address cellular exhaustion and promote long-term skin health. Its commercial strategy involves a dual-track pipeline, encompassing both prescription therapeutics and professional-grade skincare products, currently distributed through specialized aesthetic and dermatology practices across the United States under the Re-Q Health brand.
How much funding has Rapalogix Health raised?
Rapalogix Health has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2026): $20M with participation from GordonMD Global Investments and Woodline Partners
Key Investors in Rapalogix Health
GordonMD Global Investments
A Beverly Hills-based firm specializing in providing strategic investment solutions specifically tailored for the biopharmaceutical and life sciences sectors.
Woodline Partners
A San Francisco-based investment firm that utilizes a market-neutral equity strategy to generate alpha within the global healthcare and technology industries.
What's next for Rapalogix Health?
Following this major enterprise-level funding, Rapalogix Health is expected to scale its commercial operations and expand the clinical validation of its proprietary molecule. The infusion of capital will likely support the broadening of the Re-Q Health product portfolio and the advancement of its therapeutic pipeline. As the company transitions from early-stage development to a more mature commercial phase, strategic focus will remain on establishing market dominance within the high-growth longevity and aesthetic medicine sectors, ensuring that its science-first methodology remains the cornerstone of its competitive advantage.
See full Rapalogix Health company page
